Supplementary table 1: Univariate analysis of factors associated with transition from no fibrosis (F0) to fibrosis stage (≥F1) in 176 patients with CHC.

Variables	**Absence of Fibrosis (F0)** **N= 51**	**Presence of Fibrosis (≥ F1)** **N=125**	***P value***
Age	39 (19- 63)	47(26- 78)	0.0001*
Gender (Male)	22 (43.1%)	59 (47.2%)	0.034ϕ
AST (IU/L)	37(9- 254)	46 (14- 229)	0.001ɵ
ALT (IU/L)	51 (16-302)	56(11-432)	0.02 ɵ
Serum Bilirubin (mg/dL)	0.8 (0.3-3.8)	1.2(0.2-6.8)	0.01ɵ
Serum albumin (g/dL**)**	3.5 ± 1	2.8 ± 1	0.03ɵ
Platelet (× 10^9 /L)	267 (72–534)	191 (35–514)	<0.0001ɵ
HCV-RNA log^{10}	8.6X10^5 (5.2X10^3-3.8 X 10^7)	8.4 X 10^5 (3.7X10^4-1.7X10^6)	0.52ɵ
rs12979860	11 (17.7%)	51 (82.3%)	0.015ϕ
rs4803217	14 (19.7 %)	57 (80.3 %)	0.026 ϕ
rs368234815	10 (16.4%)	51 (83.6%)	0.007ϕ

ALT, alanine aminotransferase; AST, aspartate aminotransferase

*Student's *t*-test.

ϕ chi-squared test.

ɵ Mann–Whitney *U*-test

Supplementary table 2: Genotype frequencies and link of *INFL3-INFL4* SNPs with fibrosis occurrence (≥F1) in additive model

INFL3-INFL4 polymorphisms	CHC patients		OR (95% CI)	*P*-value
	No fibrosis F0 (n = 51)	Fibrosis ≥F1 (n = 125)		
rs12979860				
TT	6 (30%)	14 (70%)	Reference	0.082
CT	34 (36.2%)	60 (63.8%)	0.76 (0.27-2.15)	
CC	11 (17.7%)	51 (82.3%)	1.99 (0.62-6.32)	
rs4803217				
TT	5 (31.3%)	11 (68.7 %)	Reference	0.08
GT	32 (36 %)	57 (64 %)	0.81 (0.26-2.54)	
GG	14 (19.7%)	57 (80.3%)	1.85 (0.55-6.19)	
rs368234815				
ΔG/ΔG	6 (28.6%)	15 (71.4%)	Reference	0.06
TT/ΔG	35 (37.2%)	59 (62.8%)	0.67(0.23-1.9)	
TT	10 (16.4%)	51 (83.6%)	2.04(0.64-6.54)	

Supplementary table 3: Genotype frequencies and link of *INFL3-INFL4* SNPs with moderate/sever fibrosis (≥F2) in additive model

INFL3-INFL4 polymorphisms	CHC patients		OR (95% CI)	*P*-value
	Fibrosis level < F2 (n = 62)	Fibrosis level ≥F2 (n = 114)		
rs12979860				
TT	6 (30%)	14 (70%)	Reference	0.088
CT	40 (42.6%)	54 (57.4%)	0.58 (0.20-1.64)	
CC	16 (25.8%)	46 (74.2%)	1.23 (0.40-3.75)	
rs4803217				
TT	5 (31.3%)	11 (68.7 %)	Reference	0.104
GT	38 (42.7 %)	51 (57.3 %)	0.61 (0.19-1.9)	
GG	19 (26.8%)	52 (73.2%)	1.24 (0.38-4.05)	
rs368234815				
ΔG/ΔG	7 (33.3%)	14 (66.7%)	Reference	0.07
TT/ΔG	40 (42.6%)	54 (57.4%)	0.68(0.25-1.8)	
TT	15 (24.6%)	46 (75.4%)	1.53(0.52-4.5)	

Supplementary table 4: Genotype frequencies and link of *INFL3-INFL4* SNPs with cirrhosis (=F4) in additive model

INFL3-INFL4 polymorphisms	CHC patients		OR (95% CI)	*P*-value
	NO cirrhosis F0-F3 (n = 118)	cirrhosis (F4) (n = 58)		
rs12979860				
TT	13 (65%)	7 (35%)	Reference	0.134
CT	69 (73.4%)	25 (26.6%)	0.67 (0.24-1.88)	
CC	36 (58.1%)	26 (41.9%)	1.34 (0.47-3.83)	
rs4803217				
TT	10 (62.5%)	6 (37.5 %)	Reference	0.06
GT	67 (75.3 %)	22 (24.7 %)	0.55 (0.18-1.7)	
GG	41 (57.8%)	30 (42.2%)	1.2 (0.4-3.73)	
rs368234815				
ΔG/ΔG	13 (61.9%)	8 (38.1%)	Reference	0.08
TT/ΔG	70 (74.5%)	24 (25.5%)	0.58 (0.21-1.5)	
TT	35 (57.4%)	26 (42.6%)	1.21 (0.44-3.3)	

Supplementary table 5: Genotype frequencies and link of *INFL3-INFL4* SNPs with fibrosis occurrence (≥F1) in recessive model

INFL3-INFL4 polymorphisms	CHC patients		OR (95% CI)	*p*-value
	No fibrosis F0 (n = 51)	Fibrosis ≥F1 (n = 125)		
rs12979860				
TT	6 (30%)	14 (70%)	Reference	0.92
CT - CC	45 (28.9%)	111 (71.1%)	1.05 (0.38-2.92)	
rs4803217				
TT	5 (31.3%)	11 (68.7 %)	Reference	0.83
GT- GG	46 (28.8 %)	114 (71.2 %)	2.2 (1.1-4.5)	
rs368234815				
ΔG/ΔG	6 (28.6%)	15 (71.4%)	Reference	0.97
TT/ΔG - TT	45 (29%)	110 (71%)	0.98(0.36-2.7)	

Supplementary table 6: Genotype frequencies and link of *INFL3-INFL4* SNPs with moderate/sever fibrosis (≥F2) in recessive model.

INFL3-INFL4 polymorphisms	CHC patients		OR (95% CI)	*P*-value
	Fibrosis level < F2 (n = 62)	Fibrosis level ≥F2 (n = 114)		
rs12979860				
TT	6 (30%)	14 (70%)	Reference	0.6
CT - CC	56 (35.9%)	100 (64.1%)	0.77 (0.28-2.1)	
rs4803217				
TT	5 (31.3%)	11 (68.7 %)	Reference	0.73
GT- GG	57 (35.6 %)	103 (64.4 %)	0.82 (0.27-2.5)	
rs368234815				
ΔG/ΔG	7 (33.3%)	14 (66.7%)	Reference	0.85
TT/ΔG - TT	55 (35.5%)	100 (64.5%)	0.91(0.35-2.4)	

Supplementary table 7: Genotype frequencies and link of *INFL3-INFL4* SNPs with cirrhosis (=F4) in recessive model.

INFL3-INFL4 polymorphisms	CHC patients		OR (95% CI)	*P*-value
	NO cirrhosis F0-F3 (n = 118)	cirrhosis (F4) (n = 58)		
rs12979860				
TT	13 (65%)	7 (35%)	Reference	0.84
CT - CC	105 (67.3%)	51 (32.7%)	0.9 (0.33-2.4)	
rs4803217				
TT	10 (62.5%)	6 (37.5 %)	Reference	0.7
GT- GG	108 (67.5 %)	52 (32.5 %)	0.8 (0.28-2.3)	
rs368234815				
ΔG/ΔG	13 (61.9%)	8 (38.1%)	Reference	0.6
TT/ΔG - TT	105 (67.7%)	50 (32.3%)	0.77 (0.3-1.99)	